Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

BACKGROUND: This study was designed to evaluate the differential effect of epidermal growth factor receptor (EGFR) mutation status (exon 19 vs. 21) on progression-free survival (PFS) and overall survival (OS) in treatment-naïve advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC) treate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lung India
Glavni autori: Joshi, Amit, Patil, Vijay, Noronha, Vanita, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Format: Artigo
Jezik:Inglês
Izdano: Medknow Publications & Media Pvt Ltd 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5760863/
https://ncbi.nlm.nih.gov/pubmed/29319030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/lungindia.lungindia_201_17
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items